US 11,872,361 B2
Systems and methods for selectively occluding the superior vena cava for treating heart conditions
Navin K. Kapur, Hanover, MA (US); and Richard H. Karas, Franklin, MA (US)
Assigned to Tufts Medical Center, Inc., Boston, MA (US)
Filed by Tufts Medical Center, Inc., Boston, MA (US)
Filed on Nov. 19, 2020, as Appl. No. 16/953,220.
Application 16/953,220 is a continuation in part of application No. 16/402,194, filed on May 2, 2019, granted, now 10,842,975.
Application 16/402,194 is a continuation in part of application No. 16/168,357, filed on Oct. 23, 2018, granted, now 10,842,974.
Application 16/168,357 is a continuation in part of application No. 15/753,300, granted, now 10,758,715, issued on Sep. 1, 2020, previously published as PCT/US2016/047055, filed on Aug. 15, 2016.
Application 15/753,300 is a continuation in part of application No. 15/203,437, filed on Jul. 6, 2016, granted, now 10,279,152, issued on May 7, 2019.
Application 16/402,194 is a continuation of application No. 15/203,437, filed on Jul. 6, 2016, granted, now 10,279,152, issued on May 7, 2019.
Application 15/203,437 is a continuation of application No. 14/828,429, filed on Aug. 17, 2015, granted, now 9,393,384, issued on Jul. 19, 2016.
Claims priority of provisional application 62/939,524, filed on Nov. 22, 2019.
Claims priority of provisional application 62/642,569, filed on Mar. 13, 2018.
Claims priority of provisional application 62/576,529, filed on Oct. 24, 2017.
Prior Publication US 2021/0077792 A1, Mar. 18, 2021
Int. Cl. A61M 25/10 (2013.01); A61B 5/00 (2006.01); A61B 5/0215 (2006.01); A61B 5/024 (2006.01); A61B 5/026 (2006.01); A61B 17/12 (2006.01); A61M 60/40 (2021.01); A61M 60/135 (2021.01); A61M 60/268 (2021.01); A61M 60/871 (2021.01); A61M 60/515 (2021.01); A61B 5/29 (2021.01); A61B 17/00 (2006.01)
CPC A61M 25/10184 (2013.11) [A61B 5/026 (2013.01); A61B 5/0215 (2013.01); A61B 5/02438 (2013.01); A61B 5/29 (2021.01); A61B 5/6853 (2013.01); A61B 5/6858 (2013.01); A61B 5/746 (2013.01); A61B 17/1204 (2013.01); A61B 17/12036 (2013.01); A61B 17/12109 (2013.01); A61B 17/12136 (2013.01); A61M 60/135 (2021.01); A61M 60/268 (2021.01); A61M 60/40 (2021.01); A61M 60/515 (2021.01); A61M 60/871 (2021.01); A61B 17/12172 (2013.01); A61B 2017/00022 (2013.01); A61B 2017/00044 (2013.01); A61B 2017/00115 (2013.01); A61B 2017/00154 (2013.01); A61B 2017/00199 (2013.01); A61B 2017/00221 (2013.01); A61B 2017/00398 (2013.01); A61B 2017/00411 (2013.01); A61B 2017/00734 (2013.01); A61B 2017/00889 (2013.01); A61M 25/10188 (2013.11); A61M 2025/1052 (2013.01); A61M 2205/3331 (2013.01); A61M 2230/005 (2013.01); A61M 2230/30 (2013.01)] 27 Claims
OG exemplary drawing
 
1. A method for modulating a heart of a patient for performing a cardiac procedure, the method comprising:
inserting a catheter comprising a flow limiting element into a superior vena cava (SVC) of the patient such that the flow limiting element is disposed within the SVC;
actuating the flow limiting element within the SVC, thereby at least partially occluding the SVC;
measuring a parameter related to the heart of the patient to generate a measured parameter;
determining whether the measured parameter satisfies a predetermined threshold; and
performing the cardiac procedure at the heart of the patient if the measured parameter is determined to satisfy the predetermined threshold.